Who was studied, and how
Three numbers in the abstract
Where each one falls
Where it lands on the map
What it changes
Among 8 other studies
1,873people with cardiovascular disease, in this paper
The trial randomly assignedassigned by chance
simvastatin-ezetimibe
placebo
Reduced ischemic cardiovascular events−22%
No clear effect on composite of major cardiovascular events−4%
No clear effect on aortic-valve replacement+0%
randomisedthe abstract, start to end
… in the simvastatin-ezetimibe group, 0.96; 95% confidence interval [CI], …
… in the placebo group (hazard ratio, 1.00; 95% CI, 0.84 to 1.18; P=0.97).
… group (187 patients) (hazard ratio, 0.78; 95% CI, 0.63 to 0.97; P=0.02), …
← favours treatmentfavours comparator →
could be chanceComposite of major cardiovascular eventssimvastatin-ezetimibe vs placebo
HR 0.960.83–1.12
Aortic-valve replacementsimvastatin-ezetimibe vs placebo
HR 1.000.84–1.18
Ischemic cardiovascular eventssimvastatin-ezetimibe vs placebo
HR 0.780.63–0.97
StatinsOther lipid agentsCardiovascular eventsCardiac & vascular function
Other lipid agents × cardiovascular eventshelps?settled
unlikelylikely
0.800.80 without it
Statins × cardiovascular eventshelps?replicated
unlikelylikely
0.860.86 without it
Other lipid agents × cardiac & vascular functionhelps?mixed
unlikelylikely
0.000.00 without it
← favours treatmentfavours comparator →
1 / 6